Olema Oncology to Present Preclinical Data for Palazestrant and OP-3136 at the 2026 AACR Annual Meeting

SAN FRANCISCO, March 17, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced it